4-(3-nitrophenyl)-6-phenyl-3-pyridazinecarboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(3-nitrophenyl)-6-phenyl-3-pyridazinecarboxamide
• 英文别名: 4-(3-nitrophenyl)-6-phenylpyridazine-3-carboxamide
• 化学式: C₁₇H₁₂N₄O₃
• 分子量: 320.307
• InChiKey: GBMNAZGSHXTNJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  115
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  氨基甲醇 、 ethyl 4-(3-nitrophenyl)-6-phenyl-3-pyridazinecarboxylate 以 甲醇 、 二氯甲烷 为溶剂， 生成 4-(3-nitrophenyl)-6-phenyl-3-pyridazinecarboxamide
  参考文献：
  名称：

  Morpholine containing pyridine compounds, compositions and use

  摘要：

  一种含氮杂环化合物，化学式为：##STR1##其中R.sup.1是较低的烷基，可选择地取代为羟基、卤素或杂环基，羧基、酯化羧基、羰基取代的羰基，可选择地取代为杂环(较低)烷基或较低烷基氨基(较低)烷基的含氮杂环羰基，可选择地取代为较低烷基的含氮杂环羰基，或可选择地取代为较低烷基氨基(较低)烷基的脲基，R.sup.3是氢或卤素；R.sup.2是取代硝基的苯基，X是.dbd.N--或##STR2##其中R.sup.4是较低的烷基或卤代(较低)烷基，或与R.sup.1共同形成可选择地取代为氧代和较低烷基氨基(较低)烷基的含氮杂环基；或R.sup.2是较低烷基，X是##STR3##其中R.sup.4是取代硝基的苯基；以及其药学上可接受的盐，其制备方法和包含相同的药物(例如抗高血压)组合物。

  公开号：

  US04857527A1

文献信息

• Morpholine containing pyridine compounds, compositions and use
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04857527A1

  公开（公告）日：1989-08-15

  An N-containing heterocyclic compound of the formula: ##STR1## wherein R.sup.1 is lower alkyl optionally substituted with hydroxy, halogen or a heterocyclic group, carboxy, esterified carboxy, carbamoyl optionally substituted with heterocyclic(lower)alkyl or lower alkylamino(lower)alkyl, N-containing heterocycliccarbonyl optionally substituted with lower alkyl, or ureido optionally substituted with lower alkylamino(lower)alkyl, and R.sup.3 is hydrogen or halogen; R.sup.2 is phenyl substituted with nitro, and X is .dbd.N--or ##STR2## in which R.sup.4 is lower alkyl or halo(lower)alkyl, or is taken together with R.sup.1 to form an N-containing heterocyclic group optionally substituted with oxo and lower alkylamino(lower)alkyl; or R.sup.2 is lower alkyl, and X is ##STR3## in which R.sup.4 is phenyl substituted with nitro; and a pharmaceutically acceptable salt thereof, processes for the preparation thereof and pharmaceutical (e.g. antihypertension) compositions comprising the same.

  一种含氮杂环化合物，化学式为：##STR1##其中R.sup.1是较低的烷基，可选择地取代为羟基、卤素或杂环基，羧基、酯化羧基、羰基取代的羰基，可选择地取代为杂环(较低)烷基或较低烷基氨基(较低)烷基的含氮杂环羰基，可选择地取代为较低烷基的含氮杂环羰基，或可选择地取代为较低烷基氨基(较低)烷基的脲基，R.sup.3是氢或卤素；R.sup.2是取代硝基的苯基，X是.dbd.N--或##STR2##其中R.sup.4是较低的烷基或卤代(较低)烷基，或与R.sup.1共同形成可选择地取代为氧代和较低烷基氨基(较低)烷基的含氮杂环基；或R.sup.2是较低烷基，X是##STR3##其中R.sup.4是取代硝基的苯基；以及其药学上可接受的盐，其制备方法和包含相同的药物(例如抗高血压)组合物。
• Di phenylpyridazine compounds, processes for the preparation thereof and
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US04931453A1

  公开（公告）日：1990-06-05

  The invention relates to diphenylpyridazine compounds useful in the treatment of cerebrovascular disease, of the formula: ##STR1## wherein R.sup.1 is piperazinyl(lower)alkyl, carbamoyl substituted with piperazinyl(lower)alkyl, or piperazinylcarbonyl, in each of which a piperazinyl group may be substituted with lower alkyl, R.sup.2 is phenyl substituted with nitro, and R.sup.3 is hydrogen or halogen, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种用于治疗脑血管疾病的二苯吡嗪化合物，其化学式为：##STR1## 其中R.sup.1是哌嗪基（较低）烷基，用哌嗪基（较低）烷基取代的氨基甲酰基，或哌嗪基甲酰基，其中哌嗪基可以被较低烷基取代；R.sup.2是取代有硝基的苯基；R.sup.3是氢或卤素，或其药学上可接受的盐。
• N-containing heterocyclic compounds, and composition comprising the same
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04990507A1

  公开（公告）日：1991-02-05

  The invention relates to a pharmaceutical composition as a therapeutic agent for ischemic disease comprising a compound of the formula ##STR1## wherein R.sup.1 is carbamoyl substituted with morpholino (lower) alkyl, thiomorpholino(lower)alkyl or lower alkylamino(lower)alkyl; or ureido substituted with lower alkylamino(lower)alkyl; and R.sup.2 is phenyl substituted with nitro, and R.sup.4 is lower alkyl; or R.sup.2 is lower alkyl, and R.sup.4 is phenyl substituted with nitro; with proviso that R.sup.1 is carbamoyl substituted with thiomorpholino(lower)alkyl or lower alkylamino(lower)alkyl; or ureido substituted with lower alkylamino(lower)alkyl when R.sup.4 is lower alkyl; or its salt, as an active ingredient, in association with a pharmaceutically acceptable, substantially nontoxic carrier or excipient.

  本发明涉及一种药物组合物，作为缺血性疾病的治疗剂，包括式中的化合物：##STR1##其中，R.sup.1是以吗啡环(lower)烷基、硫代吗啡环(lower)烷基或(lower)烷基氨(lower)烷基取代的氨基甲酰基；或以(lower)烷基氨(lower)烷基取代的脲基；R.sup.2是以硝基取代的苯基，R.sup.4是(lower)烷基；或R.sup.2是(lower)烷基，R.sup.4是以硝基取代的苯基；但前提是当R.sup.4是(lower)烷基时，R.sup.1是以硫代吗啡环(lower)烷基或(lower)烷基氨(lower)烷基取代的氨基甲酰基或以(lower)烷基氨(lower)烷基取代的脲基；或其盐，作为活性成分，与药学上可接受的、基本无毒的载体或赋形剂相结合。
• N-containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0228845B1

  公开（公告）日：1990-12-12
• US4831030A
  申请人：——

  公开号：US4831030A

  公开（公告）日：1989-05-16